Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Study reports on clinical effectiveness of ne direct visualization system

Boston Scientific : 21 May, 2008  (Company News)
Boston Scientific has released results from an international, multi-centre patient registry documenting favourable safety and clinical utility data for its SpyGlass Direct Visualization System, which offers extensive visual access to the biliary tract.
Results from the registry were presented by Yang K Chen, MD, Division of Gastroenterology and Hepatology, University of Colorado at Denver and Health Services Center and lead investigator, at Digestive Disease Week (DDW) in San Diego, California, USA. Two additional subset analyses from the SpyGlass patient registry were also presented at the conference.

The patient registry reports on clinical data from 296 patients at 15 medical centres (10 US and five European sites) who required peroral cholangioscopy (PO) for stone therapy or investigation of suspected pathology with or without biopsy. Results of the study indicate that PO using the SpyGlass System can be safely performed by a single operator and provides reliable access to target sites for visual inspection and stone therapy. In addition, the SpyBite Biopsy Forceps were found to obtain adequate histologic tissue specimens.

'The SpyGlass registry provides important information to physicians in assessing the safety and clinical effectiveness of the system,' said Dr Chen. 'Preliminary results demonstrate that visual examination combined with directed tissue sampling using the SpyGlass System may improve accuracy of diagnosis in patients with indeterminate bile duct lesions.'

The SpyGlass System is the first single-use direct visualization system that requires only a single physician operator and provides four-way steerability in a four lumen single-use catheter. The Catheter provides two dedicated irrigation channels in addition to a 1.2mm working channel through which diagnostic and therapeutic devices can be used in the biliary ducts. The system includes a miniature 6,000-pixel fibre optic probe attached to a camera that provides physicians with a direct view of a patient's bile ducts, overcoming some of the visual challenges of conventional endoscopic retrograde cholangiography procedures (ERCP).

As part of the international multi-centre SpyGlass registry, Mansour Parsi, MD, Department of Gastroenterology and Hepatology at the Cleveland Clinic, also reported on clinical data from 98 patients, demonstrating that peroral cholangioscopy using the SpyGlass System is safe and effective for the treatment of difficult-to-remove biliary stones. In addition, Dr. Parsi concluded that the rate of missed stones by an ERCP may be higher than previously reported and more research is required.

An additional subset analysis from the patient registry, led by Douglas Pleskow, MD, director, Colon Cancer Center and co-director, GI Endoscopy at Beth Israel Deaconess Medical Center in Boston, involved 136 patients with indeterminate biliary strictures or filling defects who underwent an ERCP followed by peroral cholangioscopy using the SpyGlass System and the SpyBite Biopsy Forceps. The study results indicate that targeted biopsies using the SpyGlass System are feasible and safe, and provide specimens adequate for histology in 89 percent of cases.

Preliminary results also show that biliary biopsies obtained under direct visualization by peroral cholangioscopy using the SpyBite Biopsy Forceps can be useful in selected clinical situations including histologic confirmation of malignant or benign intrinsic lesions of the bile duct. Patient follow-up for this registry is ongoing.

'This multi-centre registry adds to the growing body of evidence that supports the benefits of the SpyGlass System for single-operator duodenoscope-assisted cholangiopancreatoscopy in performing diagnostic and therapeutic endoscopic procedures such as targeted biopsies and the management of biliary stones,' said Michael P Phalen, president, Boston Scientific Endoscopy. 'The SpyGlass System is making cholangioscopy feasible for physicians worldwide and improving the quality of healthcare for patients.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo